DelMar PHARMACEUTICALS

Breakthrough Cancer Therapeutics

JEFFREY BACHA
PRESIDENT & CEO

Safe Harbor

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Contact

DelMar Pharmaceuticals, Inc.

Jeffrey Bacha, B.Sc., MBA – President & CEO

- jbacha@delmarpharma.com

Dennis Brown Ph.D. – Chief Scientific Officer

- dbrown@delmarpharma.com

Scott Praill, CA – Chief Financial Officer

- spraill@delmarpharma.com

Corporate Headquarters:
Suite 720 – 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025
USA

Our Mission

To benefit patients and create shareholder value by rapidly developing and commercializing well-validated anti-cancer therapies in high-impact orphan cancer indications where patients have failed modern therapy.

CAPITALIZATION

Capital Raised to Date:	**$13.6 million**
Shares Outstanding:	**30.6 million**
Market Capitalization:	**$69 million**
Ticker (OTCQB):	**DMPI**
Auditor:	**PricewaterhouseCoopers LLP**

Value Proposition

- *Clinical & commercial stage oncology company*
- *Well-validated lead drug candidate: Interim clinical data presented @ Society of NeuroOncology Nov 2012*
- *Hold commercial rights to lead product in China: Near-immediate revenue opportunity*
- *Streamlined clinical and global commercialization plan*
- *DelMar clinical team successfully developed Synribo®: FDA approved by TEVA 26-Oct/2012*
- *Targeting liquidity event through public listing H1'2013*
- *Management has a history of successful exits : Matrix, Chemgenix*

VAL-083: Clinical Development in GBM

- **DelMar initiated Phase I/II Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor in 2011**
  - **Clinicaltrials.gov identifier:** NCT01478178
- **Currently Recruiting at Two Clinical Sites in USA**
  - **Sarah Cannon Cancer Research Institute (SCRI) – Nashville**
  - **SCRI – Sarasota**
- **DelMar presented interim clinical data demonstrating activity against GBM at 2012 Society for NeuroOncology Annual Meeting**

VAL-083: *DelMar's First Product Opportunity*

- **Small-molecule chemotherapeutic**
  - First-in-class chemistry
  - Novel alkylating agent
- **Well studied in previous human clinical studies**
  - >40 published clinical trials in multiple indications sponsored by the U.S. National Cancer Institute (NCI)
  - Approved cancer chemotherapy in China for treatment of leukemia & lung cancer
- **Pharmacokinetics/Pharmacodynamics**
  - Orally bioavailable and readily reaches brain tumors
- **Favorable safety profile**
  - Published data and commercial experience in China demonstrates fewer side effects compared to other alkylating agents
- **Well characterized mechanism of action**
  - Distinct from other alkylating agents used in chemotherapy
- **Commercial scale manufacturing in place**
  - DelMar has patented improvements & analytical methods required for FDA cGMP

VAL-083: Development Strategy



VAL-083

Intellectual Property

Orphan Drug Protection: Provides 7 – 10 years of market exclusivity

- Granted in USA 2012
- Anticipated in EU 2013

Summary of DelMar Patent Filings

- WO 2012/024367 A2: Chemical compositions and Methods of Use
- WO 2012/024368 A2: Manufacturing
- 61-542,300: Chemical compositions and Methods of Use
- 61-589,029: Mechanism of Action
- 61-644,399: Methods of Use
- 1023-007-PR: Quality Controls
- 1023-010-PR: Mechanism of Action

GBM:
DelMar's First Target Market for VAL-083

- **Glioblastoma Multiforme (GBM): The most common and aggressive form of brain cancer**
- **Large market opportunity:**
  - Second and third-line therapy: $200 m - $500 m annual sales
  - Front line therapy: >$1 billion annual sales
- **Affects approx. 15,000 adults each year in USA**
- **Median survival without treatment = 4 ½ months**
- **Approximately half of patients tumors fail all other treatments**
- **DelMar has presented new clinical and non-clinical data supporting VAL-083 activity where other treatments fail**
  - American Association of Cancer Research (AACR): 2012
  - Society for NeuroOncology (SNO): 2012

VAL-083 Initial Target Market:

GBM Market Projections



VAL-083

Evidence of Clinical Efficacy in GBM

VAL-083 historical clinical data demonstrates comparable incremental survival benefit and overall survival comparable to standard of care

Treatment of GBM	**temozolomide** *(Phase III Stupp 2005)*	**VAL-083** *(Phase II Eagan 1979)*
Median Overall Survival *RT + Chemo*	58 weeks	67 weeks
OS Benefit of adding Chemo: *RT & Chemo vs. XRT Only*	2.5 months (p<0.01)	8.4 months (p=0.02)
Sample (n=)	573	42
Randomization	1:1	1:1





VAL-083

Efficacy: GBM – comparison to historical agents

Chemotherapy	Comparative Therapy Survival		Median Survival Benefit vs. XRT
	Radiation	Radiation + Chemotherapy	
Temodar™	12.1 months	58 weeks (14.6 months)	2.5 months
VAL-083	8.3 months	67 weeks (16.7 months)	8.0 months

Reported Radiation + Chemo Survival w/ other chemotherapeutic agents in GBM

Carmustine™ (BCNU)	40-50 weeks
Lormustine™ (CCNU)	52 weeks
Nimustine™ (ACNU)	35 weeks

Avastin™	No reported benefit to survival

GBM

Importance of MGMT Status

- Expression of MGMT is highly correlated with response to standard of care *(temozolomide + RT)*



Source: Hegi ME et al. N Engl J Med. 2005; 352(10):997-1003.

VAL-083

Active Independent of MGMT Repair Mechanism

- VAL-083 is active independent of MGMT chemo-resistance mechanism *in vitro* *(Dunn, AACR 2012)*

U251 cell line
Adult GBM
MGMT negative, TMZ sensitive





T98G
Adult GBM
MGMT positive, TMZ resistant





Toxicity Comparison

	Temodar	BCNU	VAL-083
Severe toxicity reported (>2%)	Hematologic*, nausea, vomiting, fatigue, asthenia, neuropathy	Hematologic*, pulmonary, nausea, vomiting, encephalopathy, renal	Hematologic*
*DLT			
NADR	21-28 days	21-35 days	18-21 days
Recovery	Within 14 days	42-56 days	Within 7-8 days

As reported by BC Cancer Agency monograph (2010)

literature (1970s) & China commercial experience

Illustrative Comparison of Dosing Regimen



VAL-083: Clinical Development in GBM

Interim Results to Date (study ongoing)

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Prior Therapy	XRT/TMZ/BEV	XRT/TMZ/BEV	XRT/TMZ/BEV	XRT/TMZ/BEV	XRT/TMZ/BEV	XRT/TMZ/BEV	XRT/TMZ/BEV
Rounds of VAL-083 treatment	2 VAL-083 = 1.5mg/kg	15 1.5mg/kg	2 1.5mg/kg	2 3.0mg/kg	4 3.0mg/kg	1 3.0mg/kg	2 3.0mg/kg
AE	none	none	none	none	None drug related	none	none
Tumor Response	Progressive Disease (PD)	Partial Response/SD	PD	PD	Stable Disease (SD)	n/a	n/a



Figure 1: *CT scans of patient # 5 before initiating VAL-083 treatment (on the left) and after completion of 8 weeks of treatment (to the right)* ***demonstrating stable disease.***



Figure 2: *CT scans of patient # 2 before initiating VAL-083 treatment (on the left) and after completion of 7 weeks of treatment (to the right). Treatment resulted in a volumetric reduction by 50% and improved disease symptoms, stable disease (SD) has been maintained for 15 cycles of treatment.*

Society of NeuroOncology 2012
Poster Presentation

VAL-083: Clinical Development in GBM

- Current Phase I/II Study ➔ potentially position DelMar for two multi center registration trials in second half of 2013



- ✓ **Re-confirmed published activity against GBM**
- ✓ **Well defined registration trial**
- ✓ **Registration-ready commercial scale CMC**
- ✓ **New patents claims / Orphan drug protection**

DelMar's Unique Partnership in China

Commercial and development partnership with Guangxi Wuzhou Pharmaceutical Group Co. Ltd.

- Provides DelMar with global rights to VAL-083, which is already approved as a cancer chemotherapy in China
- Near-immediate revenue opportunity for DelMar in high-growth international markets
- Guangxi Wuzhou Pharma will fund any clinical activities in China
- DelMar plans to partner China marketing rights to access an established sales force and generate royalty revenue



VAL-083: *China Approval*

- **Approved Indications:**
  - *Translated:* "chronic myelogenous leukemia and can rapidly reduce tumor size of lung cancer"
- **Dosage and Administration (Leukemia & Lung Cancer):**
  - Adult: 40mg each time, Children: 0.6-1 mg/kg
  - Once a day, 5 days per course, rest 1-2 weeks and repeat the therapy until complete remission followed with maintenance therapy, 5 days/month.
  - Adult: 25-40 mg/day, Children: 0.4-0.6 mg/kg.
  - Maintenance therapy should be given for at least six months to ensure efficacy

VAL-083:
China Opportunity

- Challenge: Current sales in China are minimal
  - Drug is not well positioned vis-à-vis standard of care in approved indications
- Solution: New data to promote sales
  - Near Term: Reposition for refractory therapy in approved indications
  - Longer Term: Expand market with new indications
- Goal: Seek collaboration for marketing to generate royalty revenue
  - Partner with incumbent China-oncology sales force

VAL-083:
China Opportunity: CML Strategy

1: Demonstrate Activity in Gleevec Resistant CML in vitro

K562: Gleevec susceptible CML *(control)*



K562-Ahi-1: Gleevec resistant CML



2: Confirm activity in Phase IV (post market) clinical study

3: Seek marketing partnerships to generate royalty revenue

Upcoming Clinical Data Presentations

American Association of Cancer Research (AACR)	Apr 6 – 10 (Washington DC)
American Society of Clinical Oncology (ASCO)	May 31 – Jun 4 (Chicago IL)
Society for NeuroOncology Annual Meeting (SNO)	Nov 21 – 24 (San Francisco CA)

Leadership & Experience

Jeffrey Bacha, BSc MBA: CEO & President

- 20 years of experience in biotech and pharmaceuticals
- Founding CEO, Inimex Pharmaceuticals
- Senior Manager & Director, KPMG Health Ventures
- Emory Univ., School of Business
- UC San Diego, BioPhysics/PreMed

Dennis Brown, PhD: Chief Scientific Officer

- 30 years cancer drug discovery and development
- Founder: Matix Pharmaceuticals (acquired by Chiron)
- Founder: Chemgenex (acquired by Cephalon)
- Harvard Medical School, Assistant Professor
- Stanford Univ. Med School, Research Associate
- NYU, PhD Radiation and Cancer Biology

DelMar PHARMACEUTICALS
Development Team

Responsible for successful development & commercialization of more than 20 oncology products.

Directors & Advisors

Bill Garner, MD,	Director, coFounder DelMar; CEO Invion Ltd. (ASX:IVX)
John K. Bell, CA	Director, President of Onbelay Capital
Victor Levin, MD	Prof. Emeritus MD Anderson Cancer Center (Neuro-Oncology)
Susan Chang, MD	Chair, NeuroOncology Department UCSF
James Perry, MD	Chair, Canadian Brain Tumor Consortium
Howard Burris, MD	Director, Sarah Cannon Cancer Research Institute
Bill Bodell, PhD	Prof. Emeritus UC Berkley (DNA Damage & Repair)
Dan Zhang, MD	SFDA Oncology Advisory Panel (China FDA)
Christine Charette	Former Biotech Analyst, BMO Nesbitt Burns
Sol Barer, PhD	Founder, Celgene

Track Record of Achievements

- Launched clinical trial in 2011
- Awarded Orphan Drug Designation by US FDA for VAL-083
- Demonstrated clinical activity with lead drug candidate
- Awarded three research grants from National Research Council of Canada
- Presentations at leading scientific & business conferences
- Acquired exclusive commercial rights to VAL-083 in China
- Filed five new patents in 2011/12
- Established a highly-experienced drug development team and advisors
- Named to “Ready to Rocket” list in 2010/2012
- 2010 Winner: Discovery Parks Business Plan Competition
- Working with leading academic centers on continued research and product development

DelMar Pharma Investment Thesis

- *Clinical-stage oncology company*
- *Proven drug candidate*
- *Streamlined clinical plan*
- *Attractive valuation*
- *Highly experienced team*
- *Potential for near-term investor exit*

Thank You

Del Mar Pharmaceuticals (BC) Ltd.

Jeffrey Bacha, B.Sc., MBA – President & CEO

- jbacha@delmarpharma.com
- +1 604 317 7022

Corporate Headquarters:
Suite 720 – 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025
USA